The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.
National Center for Tumor Diseases (NCT)
German Cancer Research Center (DKFZ)
The German Cancer Research Center (DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.
Heidelberg University Hospital
Heidelberg University Hospital is one of the most important medical centers in Germany; Heidelberg University's Medical Faculty is one of Europe's most prestigious biomedical research facilities. Their shared objective is the development of innovative diagnostics and treatments and their prompt implementation for the benefit of the patient. The hospital and faculty employ approximately 12 600 individuals and are involved in training and qualification. Every year approximately 66 000 patients are treated as inpatients or day patients in more than 50 specialized clinical departments with about 1 900 beds, with more than 1 million patients being treated as outpatients. The Heidelberg Curriculum Medicinale (HeiCuMed) is at the forefront of medical training in Germany. At present approx. 3500 prospective physicians are studying in Heidelberg.
Felix Burda Foundation
The Foundation was established by Hubert Burda and Christa Maar and carries the name of their son Felix Burda who died of colon cancer in 2001 at the age of 33. The Foundation sees its main task in creating public awareness for the benefits of the early detection of colorectal cancer and in motivating large numbers of people to participate in colorectal cancer screening.
German Network Against Colorectal Cancer
The Network connects important opinion leaders and offers an independent stage for decision makers to foster exchange of strategies, bench marking projects and all kinds of improvement to increase participation in colorectal cancer screening.
Under the Patronage of the German Cancer Society (DKG)
The German Cancer Society includes more than 7,600 individual scientific members organized in 24 working groups, 16 regional cancer societies and 34 sponsors from research-based pharmaceutical industries, scientific publishers and health insurances. All our members are active in the research and treatment of cancer with the aim to address our joint goal: the fight against cancer. The society is not only open to clinical experts of all relevant medical specialties, but also to basic researchers, medical technicians, nurses, psychologists and many other professional groups working in the field of oncology.